“Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study”
Nyland JE, Raja-Khan NT, Bettermann K, Haouzi PA, Kraschnewski, JL, Parent LJ, Grigson PS
Diabetes 2021; db210385.
doi:10.2337/db21-0385.
“The Peripheral Immune Response in Diabetic Stroke”
Bettermann K, Sinha K, Kumari R, Fox C., Simpson IA
Clin Neurol Neurosurg. 2020;195:106061. doi:10.1016/j.clineuro.2020.106061.
“The Role of Neutrophils in Mediating Stroke Outcome in the Diabetic db/db Mouse Brain Following Hypoxia-Ischemia”
Kumari R,
Bettermann K, Willing L, Sinha K, Simpson IA
Neurochem Int. 2020;139:104790. doi:10.1016/j.neuint.2020.104790.
“The Stress-Immune Response in Acute Hyperglycemic Stroke”
Bettermann K, Sinha K, Kumari R, Simpson IA
Medical Research Archives 2020;8:1-14.
doi:10.18103/mra.v8i4.2081.
“Current Status and Future Prospects of Pathophysiology based Neuroprotective Drugs for the Treatment of Vascular Dementia”
Sinha K, Sun E, Kumar R,
Bettermann K
Drug Discovery Today, 2020;25(4):793-799. doi: 10.1016/j.drudis.2020.01.003.
“Clinical Outcomes of Moderate to Severe Acute Ischemic Stroke in a Telemedicine Network”
Sinha K,
Bettermann K
J Clin Neurosci. 2019 Nov;69:160-165. doi: 10.1016/j.jocn.2019.08.003.
“Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial”
Johnston KC, Bruno A, Pauls Q, et al. for the SHINE investigators
JAMA. 2019 Jul;322(4):326-335.
“Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA”
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY et al. Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators
N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410.
“Impaired Retinal Vasoreactivity: An Early Marker of Stroke Risk in Diabetes?”
Bettermann K, Slocomb JE, Shivkumar V, Quillen D, Gardner TW, Lott ME
J Neuroimaging. 2017;27(1):78-84. doi: 10.1111/jon.12412.
“Impaired Coronary and Retinal Vasomotor Function to Hyperoxia in Individuals With Type 2 Diabetes”
Lott ME, Slocomb JE, Gao Z, Gabbay RA, Quillen D, Gardner TW,
Bettermann K
Microvasc Res. 2015 Sep;101:1-7. doi: 10.1016/j.mvr.2015.05.002.
“Validation of the DRAGON Score in a North American Cohort”
Ermak DM, Adams C, Reichwein R,
Bettermann K
J Neurol Disord Stroke 2014, 3(1): 1093.
“Impaired Retinal Vasodilator Responses in Prediabetes and Type 2 Diabetes.
Lott ME, Slocomb JE, Shivkumar V, Smith B, Quillen D, Gabbay RA, Gardner TW,
Bettermann K
Acta Ophthalmol 2013 Sep;91(6):e462-9. doi: 10.1111/aos.12129.
“Diagnostic Potential of the NMDA Receptor Peptide Assay for Acute Ischemic Stroke”
Dambinova SA,
Bettermann K, Glynn T, Tews M, Olson D, Weissman JD, Sowell RL
PLoS ONE 7(7): e42362. 2012
“Retinal Vasorectivity as a Marker for Chronic Ischemic White Matter Disease?”
Bettermann K, Slocomb J, Shivkumar V, Lott ME
J Neurol Sci. 2012;322:206–210.
“Comparison of Retinal Vasodilator and Constrictor Responses In Type 2 Diabetes”
Lott MEJ, Slocomb J, Shivkumar V, Smith B, Gabbay RA, Quillen D, Gardner TW,
Bettermann K
Acta Ophthalmologica 2012, Sep;90(6):e434-41.
“Risk of Dementia, Cognitive Function and Statin Use: The Ginkgo Evaluation of Memory Study”
Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole J, Carlson MC, Yasar S, DeKosky S, Burke GL
J Stroke Cerebrovasc Disease August 2012; 21:436-444.
“Biomarkers for Stroke: In Search of Fingerprints”
Bettermann K
J Stroke Cerebrovasc Disease 2011;20: 173-176.